Peptide-Based PET Imaging Agent for PD-L1 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular imaging technologies lack effective, non-invasive methods for rapidly assessing tumor immune microenvironment dynamics and predicting responses to immunomodulatory therapies, particularly for cancers with high PD-L1 expression.
Innovation Solution
Development of a peptide-based PET imaging agent, such as WL12, that specifically binds to PD-L1, allowing for rapid and specific detection of PD-L1 expression in tumors using a conjugate with a reporting moiety and linker, enabling real-time imaging of PD-L1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiolabeled anti-PD-L1 antibodies are used for imaging, then PD-L1 expression can be assessed non-invasively, but longer clearance times are required for enhanced contrast and lesion detection
Solution Approach 1:
The patent employs small peptide molecules instead of large antibody proteins as the imaging agent. These peptide-based radiotracers have rapid clearance kinetics (minutes to hours) compared to antibodies (days), enabling faster imaging while maintaining sufficient contrast and detection accuracy for PD-L1 expression assessment.
Solution Approach 2:
The patent changes the molecular size and pharmacokinetic parameters of the imaging agent by using peptide conjugates with radiolabeled amino acids (such as 18F-FET, 18F-FDDA) instead of conventional antibody-based tracers. This parameter change optimizes the balance between imaging quality and clearance time.
2Measurement precision
If conventional IHC methods are used, then PD-L1 expression can be measured, but only a snapshot of the dynamic tumor immune milieu is provided and treatment response prediction is inaccurate
Solution Approach 1:
The patent replaces the static, invasive tissue-based IHC measurement system with a dynamic, non-invasive molecular imaging system using PET/CT. The radiolabeled peptide tracers provide quantitative, real-time assessment of PD-L1 expression and tumor immune microenvironment dynamics in vivo, enabling monitoring of temporal changes and treatment response.
Solution Approach 2:
The patent creates a multi-functional imaging platform that can simultaneously assess PD-L1 expression levels, tumor immune microenvironment characteristics, and treatment response dynamics through a single non-invasive imaging procedure, providing comprehensive information for treatment decision-making.
3Productivity
If peptide-based imaging agents are used, then rapid and real-time assessment is achieved, but the binding specificity for PD-L1 must be ensured
Solution Approach 1:
The patent divides the imaging agent into modular components: a peptide sequence (such as WL12) that provides PD-L1 binding specificity and a radiolabeled amino acid component that provides the reporting function. This segmentation allows independent optimization of binding affinity and imaging properties.
Solution Approach 2:
The patent uses peptide molecules as intermediary agents that specifically bind to PD-L1 on tumor cells and serve as carriers for the radiolabeled amino acids. These peptide intermediaries bridge the gap between the target (PD-L1) and the detection signal (radiolabel), ensuring both specificity and rapid imaging capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The imaging agent provides rapid and specific detection of PD-L1 expression in tumors, facilitating non-invasive assessment of tumor immune microenvironment dynamics and guiding immunotherapy strategies, thereby improving the efficacy of immune modulation therapies.
Implementation Method 1
the reporting moiety comprises a radiolabeled amino acid of the peptide, such as radiolabeled iodotyrosine or fluorotyrosine
Data Source
AI summary
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.